FDA approves Perjeta (pertuzumab) for people with HER2-positive metastatic breast cancer
11 June 2012 | By Roche
Roche announced that the U.S. FDA has approved PerjetaTM (pertuzumab)...
List view / Grid view
News
Novartis drug Gilenya® shows long-term efficacy and safety according to new data from extension of phase III head-to-head study
11 June 2012 | By Novartis
New long-term data for Gilenya®...
Lilly and Boehringer Ingelheim present data at the 72nd American Diabetes Association Scientific Sessions® from Phase II studies comparing investigational novel basal insulin to insulin glargine
11 June 2012 | By Boehringer Ingelheim
Eli Lilly and Company and Boehringer Ingelheim announced results from two Phase II studies...
GSK announces new 52-week data from phase III study of once-weekly albiglutide in type 2 diabetes
9 June 2012 | By GlaxoSmithKline
Detailed 52 and 32-week data from the first two Phase III studies...
New data show investigational compound dapagliflozin demonstrated significant reductions in blood sugar levels when added to sitagliptin in adults with type 2 diabetes at 24 weeks, with results maintained over 48 weeks
9 June 2012 | By AstraZeneca
AstraZeneca and Bristol-Myers Squibb Company announced results from a Phase 3 clinical study...
GSK extends tender offer for all outstanding shares of Human Genome Sciences
8 June 2012 | By GlaxoSmithKline
GSK has extended its tender offer to acquire all of the outstanding shares of HGS...
Amgen announces top-line results of Phase 3 Sensipar®/Mimpara® EVOLVE(TM) trial
8 June 2012 | By Amgen
Amgen announced top-line results of the Phase 3 EVOLVE(TM) trial...
FDA extends regulatory review period for insulin degludec and insulin degludec/insulin aspart by three months
8 June 2012 | By Novo Nordisk
Regulatory review period extended for insulins degludec & insulin degludec/insulin aspart...
Tecan and Reinnervate team up for automation of 3D cell culture
Tecan has signed a co-marketing agreement with Reinnervate, a leading company in the 3D cell culture market, to develop a range of automated solutions based on the Freedom EVO® liquid handling workstations and Reinnervate’s Alvetex®Scaffold 3D cell culturing technology.
New STELARA® (ustekinumab) five year data show consistent efficacy and safety profile in treatment of moderate to severe plaque psoriasis
7 June 2012 | By Publicis Life Brands Resolute
New efficacy and safety data...
Phenomenex celebrates 30 years of “breaking with tradition”
7 June 2012 | By Phenomenex Inc
Phenomenex proudly marks its 30th anniversary in 2012...
GSK and XenoPort receive FDA approval for Horizant® for postherpetic neuralgia
7 June 2012 | By GlaxoSmithKline
The US FDA has approved Horizant® (gabapentin enacarbil)...
BASF subsidiary Metanomics Health launches MetaMap®Tox
6 June 2012 | By BASF
Metanomics Health GmbH is launching MetaMap®Tox...
Roche’s RoACTEMRA improved rheumatoid arthritis signs and symptoms significantly more than adalimumab as single-agent therapy
6 June 2012 | By Roche
Data announced from the ADACTA study...
ORENCIA® (abatacept) demonstrates comparable efficacy to Humira® (adalimumab)
6 June 2012 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb Company have announced the results of AMPLE...
